Literature DB >> 10438873

R5 strains of human immunodeficiency virus type 1 from rapid progressors lacking X4 strains do not possess X4-type pathogenicity in human thymus.

R D Berkowitz1, A B van't Wout, N A Kootstra, M E Moreno, V D Linquist-Stepps, C Bare, C A Stoddart, H Schuitemaker, J M McCune.   

Abstract

Some individuals infected with only R5 strains of human immunodeficiency virus type 1 progress to AIDS as quickly as individuals harboring X4 strains. We determined that three R5 viruses were much less pathogenic than an X4 virus in SCID-hu Thy/Liv mice, suggesting that R5 virus-mediated rapid disease progression is associated with host, not viral, factors.

Entities:  

Mesh：

Year:  1999        PMID： 10438873      PMCID： PMC104310     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  28 in total

1.  The role of mononuclear phagocytes in HTLV-III/LAV infection.

Authors:  S Gartner; P Markovits; D M Markovitz; M H Kaplan; R C Gallo; M Popovic
Journal:  Science       Date:  1986-07-11       Impact factor: 47.728

2.  CCR5- and CXCR4-tropic HIV-1 are equally cytopathic for their T-cell targets in human lymphoid tissue.

Authors:  J C Grivel; L B Margolis
Journal:  Nat Med       Date:  1999-03       Impact factor: 53.440

3.  Evidence for a role of virulent human immunodeficiency virus (HIV) variants in the pathogenesis of acquired immunodeficiency syndrome: studies on sequential HIV isolates.

Authors:  M Tersmette; R A Gruters; F de Wolf; R E de Goede; J M Lange; P T Schellekens; J Goudsmit; H G Huisman; F Miedema
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

4.  HIV induces thymus depletion in vivo.

Authors:  M L Bonyhadi; L Rabin; S Salimi; D A Brown; J Kosek; J M McCune; H Kaneshima
Journal:  Nature       Date:  1993-06-24       Impact factor: 49.962

5.  Prognostic value of HIV-1 syncytium-inducing phenotype for rate of CD4+ cell depletion and progression to AIDS.

Authors:  M Koot; I P Keet; A H Vos; R E de Goede; M T Roos; R A Coutinho; F Miedema; P T Schellekens; M Tersmette
Journal:  Ann Intern Med       Date:  1993-05-01       Impact factor: 25.391

6.  Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population.

Authors:  H Schuitemaker; M Koot; N A Kootstra; M W Dercksen; R E de Goede; R P van Steenwijk; J M Lange; J K Schattenkerk; F Miedema; M Tersmette
Journal:  J Virol       Date:  1992-03       Impact factor: 5.103

7.  The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function.

Authors:  J M McCune; R Namikawa; H Kaneshima; L D Shultz; M Lieberman; I L Weissman
Journal:  Science       Date:  1988-09-23       Impact factor: 47.728

8.  Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms.

Authors:  Y Koyanagi; S Miles; R T Mitsuyasu; J E Merrill; H V Vinters; I S Chen
Journal:  Science       Date:  1987-05-15       Impact factor: 47.728

9.  Long-term human hematopoiesis in the SCID-hu mouse.

Authors:  R Namikawa; K N Weilbaecher; H Kaneshima; E J Yee; J M McCune
Journal:  J Exp Med       Date:  1990-10-01       Impact factor: 14.307

10.  Human immunodeficiency virus infection of the human thymus and disruption of the thymic microenvironment in the SCID-hu mouse.

Authors:  S K Stanley; J M McCune; H Kaneshima; J S Justement; M Sullivan; E Boone; M Baseler; J Adelsberger; M Bonyhadi; J Orenstein
Journal:  J Exp Med       Date:  1993-10-01       Impact factor: 14.307
View more
  9 in total

1.  Increased mucosal transmission but not enhanced pathogenicity of the CCR5-tropic, simian AIDS-inducing simian/human immunodeficiency virus SHIV(SF162P3) maps to envelope gp120.

Authors:  Mayla Hsu; Janet M Harouse; Agegnehu Gettie; Clarisa Buckner; James Blanchard; Cecilia Cheng-Mayer
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

2.  Pathogenesis of primary R5 human immunodeficiency virus type 1 clones in SCID-hu mice.

Authors:  R M Scoggins; J R Taylor; J Patrie; A B van't Wout; H Schuitemaker; D Camerini
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

3.  Infectious simian/human immunodeficiency virus with human immunodeficiency virus type 1 subtype C from an African isolate: rhesus macaque model.

Authors:  T Ndung'u; Y Lu; B Renjifo; N Touzjian; N Kushner; V Pena-Cruz; V A Novitsky; T H Lee; M Essex
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

4.  Cytopathicity of human immunodeficiency virus type 1 primary isolates depends on coreceptor usage and not patient disease status.

Authors:  J F Kreisberg; D Kwa; B Schramm; V Trautner; R Connor; H Schuitemaker; J I Mullins; A B van't Wout; M A Goldsmith
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

5.  Construction and analysis of an infectious human Immunodeficiency virus type 1 subtype C molecular clone.

Authors:  T Ndung'u; B Renjifo; M Essex
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 6.  Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo.

Authors:  Matthew D Marsden; Jerome A Zack
Journal:  J Virol       Date:  2007-03-28       Impact factor: 5.103

Review 7.  HIV-1 replication and pathogenesis in the human thymus.

Authors:  Eric G Meissner; Karen M Duus; Rebecca Loomis; Rhiannon D'Agostin; Lishan Su
Journal:  Curr HIV Res       Date:  2003-07       Impact factor: 1.581

8.  Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS.

Authors:  Jasminka Sterjovski; Melissa J Churchill; Anne Ellett; Lachlan R Gray; Michael J Roche; Rebecca L Dunfee; Damian F J Purcell; Nitin Saksena; Bin Wang; Secondo Sonza; Steven L Wesselingh; Ingrid Karlsson; Eva-Maria Fenyo; Dana Gabuzda; Anthony L Cunningham; Paul R Gorry
Journal:  Retrovirology       Date:  2007-12-12       Impact factor: 4.602

9.  Validation of the SCID-hu Thy/Liv mouse model with four classes of licensed antiretrovirals.

Authors:  Cheryl A Stoddart; Cheryl A Bales; Jennifer C Bare; George Chkhenkeli; Sofiya A Galkina; April N Kinkade; Mary E Moreno; José M Rivera; Rollie E Ronquillo; Barbara Sloan; Paul L Black
Journal:  PLoS One       Date:  2007-08-01       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.